A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled

Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.

1 sources · 1 articles · updated 2026-11-03 09:35 UTC · business